Skip to main content
. Author manuscript; available in PMC: 2015 Feb 10.
Published in final edited form as: J Pharm Sci Pharmacol. 2014 Mar;1(1):82–85. doi: 10.1166/jpsp.2014.1008

Figure 1.

Figure 1

Phosphortlated Smad3 is stabilized by ERG in ERG-positive prostate cancer cells. Smad3 is phosphorylated by TGF-β binding to receptor. Phosphorylated Smad3 forms a complex with phosphorylated Smad2 and the common Smad (Smad4) and translocates to the nucleus. Phosphorylated Smad3 is stabilized by binding to ERG in the nucleus.